1459-LCP2调控SUV39H1轴介导NK/T细胞淋巴瘤耐药研究 episode artwork

EPISODE · Aug 19, 2026 · 20 MIN

1459-LCP2调控SUV39H1轴介导NK/T细胞淋巴瘤耐药研究

from 聊聊Sci

这项研究揭示了LCP2蛋白在自然杀伤/T细胞淋巴瘤(NKTCL)化疗耐药中的核心调控作用。研究发现,化疗诱导的细胞衰老会导致LCP2表达下调,进而激活IQGAP2/LaminA/C/SUV39H1信号轴,促使肿瘤细胞产生耐药性并形成免疫抑制微环境。实验数据表明,LCP2的缺失与患者病情复发及较差的预后密切相关。通过联合使用衰老抑制剂Epitalon和SUV39H1抑制剂Chaetocin,可以有效清除衰老细胞并逆转耐药。该发现不仅确定了LCP2作为衰老相关耐药的关键生物标志物,还为治疗难治性淋巴瘤提供了全新的衰老靶向治疗方案。References:Zhang Y, Qian S, Yang Q, et al. LCP2 mediates SUV39H1-driven cellular senescence-related chemoresistance in natural killer/T-cell lymphoma[J]. Cell Death & Disease, 2026.前往小宇宙评论区与主播互动

Episode metadata supplied by the publisher feed · Published Aug 19, 2026

Embed this episode

Ready to play

1459-LCP2调控SUV39H1轴介导NK/T细胞淋巴瘤耐药研究

0:00 20:56

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of 聊聊Sci?

This episode is 20 minutes long.

When was this 聊聊Sci episode published?

This episode was published on August 19, 2026.

Can I download this 聊聊Sci episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!